Abstract - 595879 Disclosed are 1-[3-(arylamino)-pyrido[2,3-b]pyrazin-6-yl]-3-alkyl-urea derivatives as represented by the general formula (I), wherein R1 is NR7R8； R7 is selected from hydrogen or alkyl； R8 independently is selected from aryl or heteroaryl and wherein the aryl- or heteroaryl substituents for their part are optionally substituted； R2 is hydrogen； R3 and R4 are independently of one another selected from hydrogen or NR9R10, assuming that if R3 = NR9R10, R4 = H, and if R4 = NR9R10, R3 = H； R9 is selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl and the alkyl-, cycloalkyl-, heterocyclyl-, aryl- and heteroaryl-, alkyl-cycloalkyl, alkylheterocyclyl, alkyl-aryl or alkyl-heteroaryl substituents for their part are optionally substituted； R10 is selected from: C(Y)NR11R12 (wherein Y = O or S), C(Y)NR13R14 (wherein Y = NH) or R10 is selected from C(NR15)R16； and wherein the other substituents are as defined herein. Representative compounds include 1-ethyl-3-(3-p-tolylamino-pyrido[2,3-b]pyrazin-6-yl)-urea, 1-ethyl-3-[3-(4-methoxy-phenylamino)-pyrido[2,3-b]pyrazin-6-yl]-urea, 1-ethyl-3-[3-(5-methyl-pyridin-2-ylamino)-pyrido[2,3-b]pyrazin-6-yl]-urea, 1-ethyl-3-[3-(1-methyl-1H-pyrazol-3-ylamino)-pyrido[2,3-b]pyrazin-6-yl]-urea, 1-ethyl-3-[3-(quinolin-3-ylamino)-pyrido[2,3-b]pyrazin-6-yl]-urea, 1-[3-(benzothiazol-6-ylamino)-pyrido[2,3-b]pyrazin-6-yl]-3-ethyl-urea, 1-[3-(4-chloro-2-methoxy-5-methylphenylamino)-pyrido[2,3-b]pyrazin-6-yl]-3-ethyl-urea, 2-chloro-4-[6-(3-ethyl-ureido)-pyrido[2,3-b]pyrazin-3-ylamino]-benzoic acid, 1-ethyl-3-[3-(1H-indol-6-ylamino)-pyrido[2,3-b]pyrazin-6-yl]-urea and 1-ethyl-3-[3-(3-oxo-3,4-dihydro-2Hbenzo[1,4]oxazin-7-ylamino)-pyrido[2,3- b]pyrazin-6-yl]-urea. Further disclosed is a pharmaceutical composition comprising a pharmacologically active quantity of at least one compound as defined above, for use in the treatment of conditions such as in
